Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2016 Oct;8(10):E1311-E1316.
doi: 10.21037/jtd.2016.10.82.

Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation

Hidetoshi Hayashi  1 , Kazuhiko Nakagawa  1
Affiliations
Editorial

Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation

Hidetoshi Hayashi et al. J Thorac Dis. 2016 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Hidetoshi Hayashi has received lecture fees from AstraZeneca K.K., Bristol Myers Squibb, and Ono Pharmaceutical Co. Ltd.; research funding from Ono Pharmaceutical Co. Ltd.; as well as advisory fees from AstraZeneca K.K. and Boehringer Ingelheim Japan Inc. Kazuhiko Nakagawa has received lecture fees and advisory fees from Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., and Nippon Boehringer Ingelheim Co. Ltd.

Comment on

References

    1. Watanabe S, Hayashi H, Nakagawa K. Is afatinib a treatment option for brain metastases in patients with EGFR mutation-positive non-small cell lung cancer? Ann Transl Med 2016;4:225. 10.21037/atm.2016.05.48 - DOI - PMC - PubMed
    1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6. 10.1038/nature05945 - DOI - PubMed
    1. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-53. 10.1200/JCO.2009.22.6993 - DOI - PMC - PubMed
    1. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-24. 10.1158/1078-0432.CCR-08-1018 - DOI - PubMed
    1. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94. 10.1056/NEJMoa1214886 - DOI - PubMed

LinkOut - more resources